Bacterial Vaginosis (Infectious Disease) - Drugs in Development, 2021

March 2021 | 82 pages | ID: B15CCF66ABF9EN
Global Markets Direct

Abstracts

Bacterial Vaginosis (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Drugs in Development, 2021, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 3, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Bacterial Vaginosis - Overview
Bacterial Vaginosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacterial Vaginosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Vaginosis - Companies Involved in Therapeutics Development
Dare Bioscience Inc
Evofem Biosciences Inc
Ferring Pharmaceuticals Inc
Guangdong Longchuangji Pharmaceutical Co Ltd
Hammock Pharmaceuticals Inc
Hennepin Life Sciences LLC
Melinta Therapeutics Inc
MyBiotics Pharma Ltd
Next Science Ltd
Osel Inc
PhagoMed Biopharma GmbH
Pharmiva AB
Profem GmbH
Starpharma Holdings Ltd
TenNor Therapeutics Ltd
Toltec Pharmaceuticals LLC
Bacterial Vaginosis - Drug Profiles
(citric acid + lactic acid + potassium bitartrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clindamycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LACTIN-V - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBXSD-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metronidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PM-477 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prof-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radezolid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
subtilosin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNP-2198 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacterial Vaginosis - Dormant Projects
Bacterial Vaginosis - Discontinued Products
Bacterial Vaginosis - Product Development Milestones
Featured News & Press Releases
Dec 07, 2020: Dar? Bioscience announces positive topline results from DARE-BVFREE, a phase 3 trial of DARE-BV1 in patients diagnosed with bacterial vaginosis
Sep 25, 2020: VivaGel BV secures TGA approval for prevention of BV
Aug 20, 2020: Dar? Bioscience announces publication of DARE-BV1 proof of concept study for the treatment of bacterial vaginosis
Jun 17, 2020: Dar? Bioscience announces initiation of pivotal Phase 3 study of DARE-BV1 in patients with bacterial vaginosis
Jun 16, 2020: VivaGel BV launched in central and eastern European countries
May 13, 2020: Osel’s live biotherapeutic product demonstrates efficacy in phase 2b study of bacterial vaginosis
Apr 28, 2020: Dare Bioscience CEO to participate in Maxim Group’s Infectious Disease Virtual Conference
Mar 10, 2020: Dare Bioscience receives FDA fast track designation for DARE-BV1 for the treatment of bacterial vaginosis
Dec 18, 2019: Dar? Bioscience announces FDA clearance of IND application for DARE-BV1 for Bacterial Vaginosis to commence pivotal phase 3 clinical study
Nov 13, 2019: Starpharma announces UK launch of VivaGel BV
Sep 28, 2019: Congratulations to Guangdong Longchuangji Pharmaceutical a subsidiary of Qiangji Pharmaceutical, for obtaining clinical approval for the "Vaginal Lactobacillus Double Live Capsules" developed
Sep 03, 2019: VivaGel BV regulatory approvals continue in Asia
Aug 15, 2019: First Asian regulatory approvals received for VivaGel BV
Aug 12, 2019: Dar? Bioscience receives QIDP Designation from the FDA for DARE-BV1 for the treatment of Bacterial Vaginosis
Aug 08, 2019: Dare announces presentation of positive clinical findings for vaginal administration of novel formulation of clindamycin phosphate for the treatment of bacterial vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Bacterial Vaginosis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Bacterial Vaginosis - Pipeline by Dare Bioscience Inc, 2021
Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, 2021
Bacterial Vaginosis - Pipeline by Ferring Pharmaceuticals Inc, 2021
Bacterial Vaginosis - Pipeline by Guangdong Longchuangji Pharmaceutical Co Ltd, 2021
Bacterial Vaginosis - Pipeline by Hammock Pharmaceuticals Inc, 2021
Bacterial Vaginosis - Pipeline by Hennepin Life Sciences LLC, 2021
Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, 2021
Bacterial Vaginosis - Pipeline by MyBiotics Pharma Ltd, 2021
Bacterial Vaginosis - Pipeline by Next Science Ltd, 2021
Bacterial Vaginosis - Pipeline by Osel Inc, 2021
Bacterial Vaginosis - Pipeline by PhagoMed Biopharma GmbH, 2021
Bacterial Vaginosis - Pipeline by Pharmiva AB, 2021
Bacterial Vaginosis - Pipeline by Profem GmbH, 2021
Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, 2021
Bacterial Vaginosis - Pipeline by TenNor Therapeutics Ltd, 2021
Bacterial Vaginosis - Pipeline by Toltec Pharmaceuticals LLC, 2021
Bacterial Vaginosis - Dormant Projects, 2021
Bacterial Vaginosis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bacterial Vaginosis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021